Overweight people may have impaired antibody response to COVID-19 infection

University of Queensland-led research shows being overweight can impair the body's antibody response to SARS-CoV-2 infection but not to the protection offered by vaccination.

Research lead, School of Chemistry and Molecular Biosciences PhD candidate Marcus Tong, said the finding built on the team's existing research on how COVID-19 affects people who are overweight.

We've previously shown that being overweight – not just being obese – increases the severity of SARS-CoV-2.

But this work shows that being overweight creates an impaired antibody response to SARS-CoV-2 infection but not to vaccination."

Marcus Tong, research lead, PhD candidate, School of Chemistry and Molecular Biosciences, University of Queensland

The research team collected blood samples from people who had recovered from COVID-19 and not been reinfected during the study period, approximately 3 months and 13 months post-infection.

"At 3 months post-infection, an elevated BMI was associated with reduced antibody levels," Mr Tong said.

"And at 13 months post-infection, an elevated BMI was associated with both reduced antibody activity and a reduced percentage of the relevant B cells, a type of cell that helps build these COVID-fighting antibodies."

In contrast, an elevated BMI had no effect on the antibody response to COVID-19 vaccination at approximately 6 months after the second vaccine was administered.

Associate Professor Kirsty Short said the results should help shape health policy moving forward.

"If infection is associated with an increased risk of severe disease and an impaired immune response for the overweight, this group has a potentially increased risk of reinfection," Dr Short said.

"It makes it more important than ever for this group to ensure they're vaccinated."

Dr Short said from a public health perspective, this data draws into question policies around boosters and lockdowns.

"We'd suggest that more personalised recommendations are needed for overweight people, both for ongoing COVID-19 management and future pandemics," she said.

"Finally, the data provides an added impetus to improve SARS-CoV-2 vaccination in low-income countries, where there's a high percentage of people who are overweight and are dependent on infection-induced immunity."

The research is published in Clinical & Translational Immunology.

Journal reference:

Tong, M., et al. (2023). Elevated BMI reduces the humoral response to SARS‐CoV‐2 infection. Clinical & Translational Immunology. doi.org/10.1002/cti2.1476.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exploring PRM-A as a novel glycan-targeted therapy for SARS-CoV-2 inhibition